Company Overview - Hofseth BioCare ASA (HBC) is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources [1] - The company upcycles by converting side streams of the salmon industry into health-improving ingredients for humans and pets [1] Product Offerings - HBC's key products include ProGo®, a mix of bioactive peptides and collagen, OmeGo®, a whole salmon oil, and CalGo® / NT-II® salmon bone powder [2] - ProGo® enhances iron metabolism, leading to increased energy and vitality [3] - OmeGo® provides immune health benefits and aids recovery from viral infections [3] - CalGo® supports bone and joint health, promoting healthy aging and active lifestyles [3] Scientific Research and Development - HBC emphasizes scientific evidence, resulting in academic partnerships and unique health benefit discoveries [3] - The company has secured patents for its findings and has identified potential therapeutics, leading to the establishment of HBC Immunology (HBCI) [3] - HBCI has raised external finance for its lead program targeting prostate cancer and ovarian cancer, along with a molecule aimed at asthma treatment [3] Corporate Structure and Location - HBC is headquartered in Ålesund, Norway, with branches in Oslo, London, Zürich, and Palo Alto [4] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [4]

Core Insights - Hofseth BioCare ASA (HBC) held an Extraordinary General Meeting on November 20, 2025, where all proposals were approved as per the notice issued on October 30, 2025 [1] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability, optimal utilization of natural resources, and full traceability [1] - The company upcycles byproducts from the salmon industry, converting waste into health-improving ingredients for humans and pets [1] Product Offerings - Key products include ProGo®, a mix of bioactive peptides and collagen; OmeGo®, a whole salmon oil; and CalGo® / NT-II®, a salmon bone powder for bone and joint health [2] - ProGo® enhances iron metabolism, leading to increased energy and vitality, while OmeGo® supports immune health and recovery from viral infections [3] - CalGo® promotes bone and joint health, aiding healthy aging and active lifestyles [3] Scientific and Academic Partnerships - HBC emphasizes scientific evidence, resulting in academic partnerships and the identification of unique health benefits [3] - The company has secured patents for its discoveries and has spun out a biotech-focused entity, HBC Immunology (HBCI), which is developing therapeutics for prostate and ovarian cancer, as well as an oral therapy for asthma [3] Corporate Structure - HBC is headquartered in Ålesund, Norway, with branches in Oslo, London, Zürich, and Palo Alto [4] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [4]

Core Insights - Hofseth BioCare (HBC) has announced a strategic partnership with Metabolic Elite to develop a premium range of performance nutrition products for elite athletes, leveraging HBC's bioactive ingredients and Metabolic Elite's advanced formulations [1][2] Company Overview - HBC is a Norwegian company focused on sustainable marine-based nutrition, utilizing side streams from the salmon industry to create health-improving ingredients such as ProGo®, OmeGo®, and CalGo® [4][5] - The company emphasizes scientific evidence and has established academic partnerships to validate the health benefits of its products, including improved iron metabolism and immune health [5][6] Product Development - The collaboration aims to enhance athletic performance through improved recovery, endurance, and metabolic efficiency, while also addressing individual metabolic needs with targeted nutrition [2][8] - HBC's ingredients are clinically proven to support metabolic health, muscle protection, energy, and weight management, making them suitable for high performers and active individuals [2][5] Leadership and Expertise - Jim LaValle, a recognized expert in precision health and the Chief Science Officer of Metabolic Elite, will guide the product formulations, bringing over 40 years of experience in metabolic optimization [3][9] - LaValle's background includes developing personalized health programs and working with various professional sports teams to enhance performance and resilience [10][12] Innovation and Patents - HBC has secured several patents for its discoveries, leading to the establishment of HBC Immunology, which focuses on potential therapeutics for conditions like prostate cancer and asthma [6]

Core Insights - HBC reported total operating revenues of NOK 54.9 million in Q3 2025, down from NOK 67.9 million in the same period last year, attributed to lower commodity prices and a weaker U.S. dollar [1] - The company experienced an EBITDA of NOK -21.1 million, with operational EBITDA at NOK -12.9 million, excluding non-recurring costs [2] - Cash and cash equivalents decreased by NOK 2.6 million, ending at NOK 65.5 million, while total liquidity, including credit facilities, was NOK 67.0 million at quarter-end [3] Financial Performance - The Midsund plant processed 5,288 tonnes of raw material, marking the highest quarterly volume in HBC's history, with a gross margin improvement to 35% from 28% [8] - Human Nutrition B2B sales surged by 200% year-over-year, driven by products like OmeGo® and ProGo®, which also won the NutraIngredients-USA "Healthy Aging" Award [8] - Consumer & Pet Health (B2C) revenues grew by 30%, supported by new European listings and product extensions [8] Product Development and Innovation - HBC focuses on sustainability and optimal utilization of natural resources, converting salmon industry by-products into health-improving ingredients [4] - Key products include ProGo®, OmeGo®, and CalGo® / NT-II®, which have shown various health benefits, including improved iron metabolism and bone health [5][6] - HBC has established academic partnerships and secured patents for its discoveries, leading to the formation of HBC Immunology, which is developing therapeutics for prostate and ovarian cancer [6] Market Position and Strategy - HBC is listed on Oslo Børs under the ticker "HBC" and emphasizes scientific evidence in its product development [7] - The company aims to enhance its equity and liquidity position following a successful private placement in October 2025 [3]

Core Points - Hofseth BioCare ASA (HBC) is conducting a private placement of new shares, with the completion of tranche 2 (T2 Offer Shares) contingent upon an extraordinary general meeting (EGM) [1] - The EGM is scheduled for 20 November 2025, and the company has secured voting commitments from shareholders to meet the majority requirement for approval [2] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources, converting by-products from the salmon industry into health-improving ingredients [3] - The company offers products such as ProGo®, OmeGo®, and CalGo® / NT-II®, which are designed to enhance human and pet health [4] Scientific and Health Benefits - HBC emphasizes scientific evidence in its product development, leading to partnerships and the identification of health benefits, including improved iron metabolism and immune health [5] - The company has secured several patents for its discoveries and has established a biotech subsidiary, AecorBio Inc., focusing on therapeutics for prostate and ovarian cancer, as well as asthma [6] Market Presence - HBC is listed on the Oslo Stock Exchange under the ticker "HBC" [7]

Core Viewpoint - Hofseth BioCare ASA ("HBC") is planning a private placement of new shares to raise between approximately NOK 155 million and NOK 181 million, aimed at capitalizing on the growing demand for salmon-derived nutrition and expanding its market presence [2][3]. Group 1: Private Placement Details - The private placement will consist of between 86,096,132 and 100,638,889 new shares at a fixed price of NOK 1.80 per share [2]. - Pre-commitments totaling approximately NOK 155 million have already been secured, with NOK 103.4 million in cash and NOK 52 million from debt conversion [2][7]. - The placement will be divided into two tranches, with Tranche 1 consisting of up to 68,555,556 shares and Tranche 2 up to 32,083,333 shares [8]. Group 2: Strategic Use of Proceeds - Proceeds will be allocated to expand the B2B ingredients unit and enhance customer adoption of nutraceutical offerings, particularly in high-growth regions like Asia and the US [3]. - Funds will support initiatives in metabolic health and healthy aging, following recent product successes and increased market interest [4]. - Investment will also focus on scaling the Brilliant Petcare brand, which is experiencing global growth in the premium pet nutrition segment [4]. Group 3: Partnerships and R&D - HBC aims to develop new concepts with global distributor partners and strengthen alliances with contract manufacturers, alongside general corporate purposes and marketing activities [5]. - The company will also allocate funds for further research and development to support its innovation pipeline [5]. Group 4: Divestment and Shareholding - In conjunction with the private placement, HBC will divest shares in AecorBio Inc. for approximately USD 5 million, reflecting a 20% valuation increase from the last funding round [6]. - Post-divestment, HBC will retain approximately 52% ownership in AecorBio [6]. Group 5: Regulatory and Application Process - The application period for the private placement starts on October 24, 2025, and is expected to close by October 27, 2025 [11]. - The completion of the private placement is subject to various conditions, including board resolutions and registration of share capital increases [12][13]. - An extraordinary general meeting (EGM) is expected to be convened around November 20, 2025, to approve the issuance of shares in Tranche 2 [15].

Core Insights - AecorBio Inc. has completed a $1.5 million equity financing round, valuing the company at $30 million, to advance its lead peptide candidate FT-002a for advanced prostate cancer [1] - FT-002a is a first-in-class peptide co-therapeutic that targets tumor iron metabolism, addressing a significant market opportunity in resistant prostate cancer, estimated at over $2.5 billion annually [2] - Preclinical data shows FT-002a can significantly reduce tumor volume, achieving an 80% reduction when combined with standard care and up to 97% in hormone-sensitive cases [3] - AecorBio is developing a multi-asset pipeline with additional preclinical programs in hormone-dependent oncology and immunology, supported by a robust intellectual property portfolio [4] - The CEO of AecorBio expressed strong investor confidence and highlighted the potential of FT-002a as a transformative therapy for treatment-resistant prostate cancer [5] Company Overview - AecorBio Inc. focuses on developing novel bioactive peptides for therapeutic applications in oncology, inflammatory, and autoimmune diseases, with FT-002a as the lead candidate [6] - The company is leveraging its proprietary peptide discovery platform to advance multiple drug candidates, supported by strong intellectual property and global academic collaborations [6] - Hofseth BioCare ASA retains approximately 67.5% ownership of AecorBio after the financing round, which will result in a NOK 8 million gain in financial income for Hofseth in Q3 2025 [5]

Core Insights - HBC has appointed Paul Bruhn as Head of New Business Development, bringing over 25 years of experience in healthcare and medical nutrition [1][2] - The company has developed a unique portfolio of bioactive ingredients derived from salmon, including OmeGo®, ProGo®, NT-II™, and PetGo®, which are scientifically backed and sustainable [3][4] - HBC emphasizes scientific evidence in its product development, leading to academic partnerships and the identification of unique health benefits [5][6] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources, upcycling side streams of the salmon industry [3][6] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [7] Product Portfolio - Key products include ProGo®, a mix of bioactive peptides and collagen; OmeGo®, a whole salmon oil; and CalGo® / NT-II®, a salmon bone powder for bone and joint health [4][5] - OmeGo® is noted for its full spectrum of Omega fatty acids, being 100% natural and clinically proven for various health benefits [3][5] Market Focus - HBC aims to address market needs for clinically backed nutrition sources, particularly in Asia, China, and the ANZ region [2][3] - The company is exploring potential therapeutics through its biotech-focused spin-off, HBC Immunology, targeting prostate and ovarian cancer, as well as asthma treatments [6]

Financial Performance - HBC recorded total operating revenues of NOK 68.4 million in Q2 2025, down from NOK 80.4 million in Q2 2024, with net operating revenues at NOK 67.8 million compared to NOK 72.2 million year-over-year [1] - EBITDA for Q2 2025 was negative NOK 5.4 million, worsening from negative NOK 2.0 million in Q2 2024, while the first six months showed a loss of NOK 25.3 million compared to NOK 18.2 million in the same period last year [2] - Operational EBITDA for Q2 2025 was positive NOK 1.3 million, an improvement from negative NOK 2.5 million in the same quarter last year, while the first six months recorded an Operational EBITDA of negative NOK 7.0 million [2] Liquidity Position - Cash and cash equivalents decreased by NOK 3.9 million during Q2 2025, totaling NOK 68.0 million at the end of the quarter, which is an increase from NOK 25.3 million a year earlier [3] - Total liquidity, including available credit lines, reached NOK 76.5 million as of June 30, 2025 [3] Product and Market Developments - Human Nutrition B2B Sales surged 180% year-over-year to NOK 9.3 million, driven by strong demand in Europe, China, and Southeast Asia [8] - OmeGo® and ProGo® led product launches, supported by scientific validation, with ProGo® winning the "Panpan Cup" Food Maker Award in China [8] - Brilliant Salmon Oil is now available in over 25 countries, with new listings in Italy, Ireland, Taiwan, UAE, and Ecuador, and further distribution agreements in Japan, Czech Republic, and Ukraine are in progress [8] Scientific and Research Advancements - HBC emphasizes scientific evidence, leading to academic partnerships and unique health benefits, including improved iron metabolism and immune health benefits from ProGo® and OmeGo® [7] - CalGo® has shown benefits for bone and joint health, supporting healthy aging and active lifestyles, with ongoing studies and publications planned for ProGo® cognitive health in Alzheimer's [8]

Group 1: ProGo® Product Overview - ProGo® is distinguished by its unique ability to activate GLP-1 and GIP receptors, supported by clinical studies demonstrating weight loss benefits [1] - ProGo® Bioactive Peptides optimize glucose and fat metabolism, enhancing energy levels and promoting a longer active lifestyle [2] Group 2: Company Background - Hofseth BioCare ASA is a Norwegian company focused on sustainability and optimal utilization of natural resources, upcycling byproducts from the salmon industry into health-improving ingredients [3] - The company offers products such as ProGo®, OmeGo® (whole salmon oil), and CalGo® / NT-II™ (salmon bone powder) aimed at improving human and pet health [3] Group 3: Scientific Evidence and Partnerships - Hofseth BioCare emphasizes scientific evidence, leading to academic partnerships and the identification of unique health benefits, including improved iron metabolism and fat reduction in overweight adults with ProGo® [4] - OmeGo® has demonstrated immune health benefits, while CalGo® supports bone and joint health, contributing to healthy aging [4] Group 4: Biotech Ventures - Hofseth BioCare has established a biotech-focused spin-off, HBC Immunology, which has raised external finance and is developing therapeutics for prostate and ovarian cancer, as well as an oral therapy for asthma [4]